Insights 
VT 
Switzerland’s consumer sentiment showed minimal change in July, recorded at -32.8 compared to the previous month’s -32.2. The third-quarter forecast for consumer sentiment is -28, marking an improvement from the second quarter’s -39 figure.
Recent developments have raised concerns, including a ruling on tariffs concerning Swiss gold. This decision also poses potential impacts on the pharmaceutical industry moving forward.
The Impact On Consumer Sentiment
The July consumer sentiment figure of -32.8 shows that Swiss households remain deeply pessimistic. While this is only a small change from the previous month, it confirms a trend of weak confidence that we’ve seen for some time. This persistent negativity will likely keep a lid on retail spending in the coming weeks.
We believe this weak data makes it highly unlikely for the Swiss National Bank to consider raising interest rates. With Swiss inflation having cooled to 1.3% as of July 2025, the central bank has more reason to be concerned about economic weakness than price pressures. This contrasts sharply with the aggressive rate hikes we saw back in 2023 when inflation was a primary concern.
This economic picture should continue to put pressure on the Swiss Franc. We have already seen the EUR/CHF exchange rate climb from 0.96 earlier in the year to test the 0.9850 level in recent weeks. Traders should consider strategies that benefit from a weaker Franc, such as buying call options on the EUR/CHF pair.
Turning to equities, the Swiss Market Index (SMI) has been struggling, losing nearly 4% since early June 2025. This downturn reflects not only the poor consumer mood but also the new concerns over trade. The market is nervous about the potential for these gold tariffs to set a precedent for other key industries.
Concerns Over The Pharmaceutical Sector
The threat to the pharmaceutical sector is particularly worrying for the Swiss market. We must remember that just two companies, Novartis and Roche, account for over 30% of the SMI’s total weight. Any negative impact on their massive export business represents a direct and significant threat to the entire index.
Given this specific risk, traders should consider buying protective put options on the SMI. This would provide a hedge against a broader market downturn if the tariff situation worsens. Buying puts on individual pharmaceutical stocks could also be a more targeted way to play this uncertainty.
However, we should note the official forecast for consumer sentiment is expected to improve to -28. This is a significant recovery from the -39 seen in the second quarter of 2025. This suggests that while the current situation is bleak, there may be some light at the end of the tunnel later in the year.
